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Abstract: Diabetic foot ulcers is a common complication of Diabetes Mellitus and was became world health global 
issue. The adjunctive therapy has become the latest modality in recent years, but there were not much 
significant research to support its utilization as a diabetic foot ulcer treatment standard. This review aims to 
assess the effectiveness of various adjunctive therapies for diabetic foot ulcers. The literature review was 
conducted through Scopus, PubMed, Embase, Ovid Technologies, CINAHL, Cochrane, and Web of Science 
databases were systematically searched for recent systematic reviews published after 2004, and randomized 
controlled trials published that evaluated treatment modalities for DFUs. Studied therapies include 
debridement, off-loading, negative pressure therapy, dressings, topical therapies, hyperbaric oxygen therapy, 
growth factors, bioengineered skin substitutes, electrophysical therapy, and alternative therapy. Good-quality 
evidence is lacking to justify the use of many of these therapies, with the exception of standard care 
(offloading, debridement) and possibly negative pressure wound therapy. Many therapeutic modalities are 
available to treat DFU. Quality high-level evidence exists for standard care such as off-loading. Evidence for 
adjunctive therapies such as negative pressure wound therapy, skin substitutes, and platelet-derived growth 
factor can help guide adjunctive care but limitations exist in terms of evidence quality.
1 INTRODUCTION 
The worldwide epedemic of type 2 diabetes mellitus 
has brought increased attention to some of its 
common complications, such as foot ulcers, 
secondary infections, and limb amputations. The 
development of diabetic ulcers in driven primarily 
by the effect of peripheral sensory neuropathy on 
foot biomechanics (foot deformity). Lower 
extremity ulcers are responsible for 20% of diabetic-
related hospital admissions and are a major source of 
morbidity and loss of income for diabetes mellitus. 
Treatment is often prolonged and is sometimes 
unsuccessful, and the patients are prone to seriuos 
complications. 
In the indonesia, diabetes mellitus (DM) afflicts 
9,9% of the population over 40 years of age, of 
which 30% suffer from lower extremity disease. 
Development of diabetic foot ulcer (DFU) is 
associated with staggeringly high mortality rates of 
16,7% at 12 months and 50% at 5 years-rates 
comarable to mortality rates of colon cancer [2]. 
Furthermore, patients with dm and new-onset dfu 
have significantly reduced survival rates compared 
with age- and ex-matched controls with dm but 
without dfus (72 and 86% 3-year survival, 
respectively) [3]. In the Indonesia, healthcare cost 
are estimated to be 5,4 times higher in the first year 
after a diagnosis of DFU than for patients with dm 
without an ulcer [2, 3]. Therefore, management and 
intervention of patients with DM and DFU must be 
adequately addressed before onset of severe 
complications. Unfortunately, dm is associated with 
a 15-25% lifetime risk for developing DFU, and 
once ulceration occurs, healing is difficult and lower 
extremity amputations (leas) common [2]. 
Fortunately, there are going efforts towards 
international consensus on management and rapid 
communication on enchancing standard of care and 
reviewing novel therapies. These therapies address 
various mechanism of dfu formation in order to 
achieve wound healing. DFU standart of care is 
critical; however, for those not responding to 
standard care, new adjunctive modalities may 
provide opportunities for healing. Yet, while 
treatment options have expanded in recent years, the 
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cost effectiveness and efficacy of these modalities 
remain in question. 
This review intends to identify recent evidence-
based evaluations of all dfu therapies, focusing 
exclusively on high-level evidence. Furthermore, it 
identifies gaps in curent data and suggests direction 
for further investigation. 
2 METHODS 
Using electronic databases, such as Scopus, 
PubMed, Embase, Ovid Technologies, Cumulative 
Index to Nursing and Allied Health Literature 
(CINAHL), Cochrane, and Web of Science 
databases were systematically searched in June 2013 
for systematic reviews published after 2004 and 
randomized controlled trials (RCTs) published in 
2012–2013. Databases were searched using the 
keywords diabetic foot, wound healing, diabetes 
complications, skin ulcer, and diabetes mellitus. 
Searches were filtered to retrieve systematic 
reviews, meta-analyses, and RCTs published in 
English. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Flow chart depicting study selection process. COSORT Consolidated Standards of Reporting Trials, MA 
meta-analysis, PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses, RCT 
randomized controlled trial, SR systematic review 
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 Records identified through search of 
database: Scopus, PubMed.grov, Ovid, 
CINAHL, CINAHL, Cocharane, Embase, and 
Web of Science 
(n = 350) 
Records after duplicates removed 
(n = 286) 
Met Inclusion criteria (n = 34) 
Randomized controlled trials (RCT), Systematic 
review (SR), Meta analysis (MA) 
 
Standard therapy 
Offloading = 3 (SR, MA) 
Debridement = 4 (SR) 
 
Other adjuvant therapies 
Dressings = 8 (SR, MA) 
Topical therapies = 6 (RCT, SR, MA) 
Electrophysical therapy = 3 (SR, MA) 
Negative pressure therapy = 5 (SR) 
Platelet-rich plasma = 4 (SR, MA) 
Cultured keratinocytes = 3 (RCT, SR) 
Growth factors/bioengineered skin subtitutes = 6 
(SR, MA) 
Hyperbaric oxygen therapy = 7 (SR, MA) 
Alternative therapy = 2 (MA, SR) 
 
 
 
Total records excluded (n = 252) 
 
Commentaries or editorials 
In vitro studies 
Conference abstract, posters, presentations 
Clinical trials published before 2011 
Reviews that did not conform to PRISMA 
guidelines 
RCTs that did not conform to CONSORT 
statement 
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3 RESULTS AND DISCUSSION 
Overall, 34 studies met inclusion and exclusion 
criteria (Table 1; Fig. 1). The modalities covered in 
these trials include negative pressure wound therapy 
(NPWT) (n = 5), growth factors (n = 3), 
bioengineered skin substitutes (BSS) (n = 6), 
cultured keratinocytes (n = 3), hyperbaric oxygen 
therapy (HBOT) (n = 7), off-loading (n = 3), 
debridement (n = 4), alternative therapies (n = 2), 
dressings (n = 8), topical therapies (n = 6), platelet-
rich plasma (PRP) (n = 4), and electrophysical 
therapy (n = 3). These studies are summarized in 
Table 1. To enhance the discussion, we first discuss 
currently accepted standard of care and then present 
the evidence supporting it. Evidence on adjuvant 
therapies not currently considered part of routine 
standard care is discussed. Finally, a summary of the 
quality of evidence is presented (Table 2). 
 
1.1 Current Standardized Approach to 
Diabetic Foot Ulcers (DFUs) 
Current standard of care for DFUs includes 
assessment for vascular disease, skin, soft tissue or 
bone infection, and neuropathy [22]. The former two 
should be addressed, if present, with optimization of 
vascular supply and antibiotics. For neuropathic foot 
ulcers, redistributing pressure (off-loading) is critical 
(see evidence discussed in Sect. 3.2). A variety of 
approaches to off-loading exist, including bed rest, 
wheelchairs, crutches, foot inserts, therapeutic 
shoes, casts, or by surgical procedures [10]. 
Although the total contact cast (TCC) is 
considered the ‘gold standard’ off-loading device by 
many because it is associated with the highest 
healing rates, it has limited use because it requires 
trained staff for application and removal, may cause 
trauma if improperly applied, and is contraindicated 
in infection, contralateral foot ulcer, significant 
arterial insufficiency, and balance problems [10]. 
Indeed, a recent study found that fewer than 2 % of 
diabetic foot specialists utilize TCC [23]. Therefore 
the ‘instant contact cast’ made by applying 
fiberglass or CobanTM (3M, Minneapolis, MN, 
USA) around a removable cast walker has been 
increasingly used and may be equally effective [24]. 
Successful off-loading is frequently affected by poor 
patient compliance, given that these devices limit 
performance of daily activities. Therefore, the best 
device is the one that best adapts to the patient and 
allows a continuous use. Some surgical procedures 
have been reported to achieve offloading, including 
Achilles tendon lengthening, silicone injections, 
metatarsal head resection, and arthroplasties [25].  
Debridement is also considered part of DFU 
standard care (see evidence discussed in Sect. 3.2). 
It allows removal of callus and abnormal edge 
tissue, necrotic tissue, and reduction of bacterial 
biofilms and excess matrix metalloproteinases 
(MMPs) [26, 27]. Debridement may be surgical, 
enzymatic (collagenase), autolytic (i.e., occlusive), 
mechanical (wet-to-dry dressing, lavage), or 
biologic (larval). Of these debridement types, 
surgical debridement is preferred for DFU. Surgical 
debridement is presumed to encourage healing by 
stimulating growth factor production and by 
converting a chronic non-healing wound 
environment into a more responsive ‘acute healing’ 
environment [27]. The optimal frequency for DFU 
debridement is not clear but often is performed 
either weekly or as needed based on the formation of 
non-viable tissue [10, 27]  
Assessment commonly includes weekly wound 
measurements and if healing is not observed (such 
as 50 % wound size reduction over 4 weeks), 
adjunctive therapies are often considered (see 
evidence discussed in Sect. 3.3). Evidence exists for 
cellular constructs (ApligrafTM, Organogenesis, 
Canton, MA and DermagraftTM, Shire, La Jolla, 
CA, USA), selected cadaveric acellular constructs 
(GraftJacketTM, KCI, San Antonio, TX, USA), and 
recombinant platelet-derived growth factor 
(RegrenexTM, Smith and Nephew, Fort Worth, TX, 
USA) for superficial wounds. Hyperbaric oxygen 
and negative pressure wound therapy are used for 
deeper or complicated wounds [27]. 
 
1.2 Evidence Supporting Standart of 
Care Above 
 
1.2.1 off-loading 
Three systematic reviews evaluated off-loading 
techniques for the treatment of DFUs. All report that 
non-removable devices are more effective than 
removable devices [25, 28, 29]. Given this finding, it 
is not recommended that therapeutic footwear be 
used to treat DFUs [28]. Compared with removable 
devices, the superiority of non-removable devices 
may be due to improved compliance [30] and/or 
decreased physical activity of subjects [31], rather 
than superior plantar pressure reduction. Only one 
review evaluated surgical off-loading procedures. 
Lewis and Lipp [25] reported that Achilles tendon 
lengthening with TCC was more effective than TCC 
alone at 7-month and 2-year follow-up (relative risk 
[RR] at 7 months 3.41, 95 % confidence interval 
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[CI] 1.42–8.18; RR at 2 years 2.23, 95 % CI 1.32–
3.76). However, this procedure is expensive, and 
long-term benefits are not well studied. The authors 
note that post-surgical scarring or worsening of 
diabetic motor neuropathy, for example, might 
decrease the benefits of Achilles tendon lengthening. 
For these reasons, it is recommended to pursue 
surgical methods only if alternative methods are 
unsuccessful. 
 
Table 2 Summary of quality of evidence for the  
             treatment of diabetic foot ulcer* 
Therapeutic intervention Quality of evidence 
Off-loading Moderate quality 
Debridement Moderate quality 
Dressings Insuficient evidence 
Topical therapies Moderate quality 
Electrophysical therapy Moderate quality 
Negative pressure wound 
therapy 
Moderate quality 
Platelet-rich plasma Moderate quality 
Cultured keratinocytes Moderate quality 
Growth factors Moderate quality 
Bioengineered skin substitutes Moderate quality 
Hyperbaric oxygen therapy Moderate quality 
Alternative therapy Insuficient evidence 
* The quality of evidence was judged by the American College of 
Physicians (ACP) criteria [21] 
 
1.2.2 Debridement 
Four systematic reviews concluded that good-quality 
evidence for a beneficial effect of debridement on 
ulcer healing is lacking [32–35]. Surgical 
debridement was evaluated in two reviews; neither 
found statistically significant improvements in 
healing with surgical debridement [32, 33]. Of note, 
subjects undergoing surgery generally received 
several days of antibiotics and were told to off-load 
the affected area for several weeks after surgery. 
Both of these factors may contribute to beneficial 
effects and neither is controlled for in available 
clinical studies. Despite this, a statistically 
significant benefit of surgical debridement was not 
found. More recently, a large retrospective review of 
312,744 wounds from 525 centers supported routine 
frequent debridement [36]. 
A Cochrane review evaluated the evidence for 
different types of debridement, including autolytic 
debridement, enzymatic debridement, and larval 
therapy, and found that autolytic debridement with 
hydrogels was superior to standard wound care, 
based on differences in healing rates (RR 1.84, 95 % 
CI 1.3–2.61) [32]. However, evaluated studies were 
small and of low quality, and the authors note that 
the benefits of hydrogels may not be limited to 
debridement, as this therapy also increases moisture 
in the wound bed [32]. Evidence is lacking for 
larvae therapy; a recent review noted that it did not 
significantly improve healing time or amputation 
risk in participants with DFUs [35]. No complete 
sets of data were found that evaluate enzymatic 
therapy for DFUs. 
 
1.3 Evidence Supporting Adjuvant 
Therapies Not Currently Considered 
Standard of Care 
 
1.3.1 Dressings 
The primary goal of dressings in patients with DFU 
is to create a moist occlusive wound environment 
that prevents infection and further trauma as well as 
absorbs chronic wound fluid. 
Multiple Cochrane reviews evaluated the 
efficacy of advanced dressings, such as hydrogels, 
foams, alginates, and hydrocolloids in DFU 
management [37–41]. Hydrogels improve healing in 
superficial DFUs compared with basic dressings; 
however, comparisons with other advanced 
dressings are lacking [41]. Studies of other dressing 
types, including silver,hydrofiber, and collagen 
dressings, found no statistically significant 
difference in wound healing compared with basic 
dressings and were limited by lack of high-quality 
data, lack of continuity in measured outcomes, and 
small sample size [42], but have found benefit for 
periwound skin. 
 
Summary: Based on our review, the data suggest that 
advanced dressings may achieve better reduction in 
contact dermatitis and periwound maceration, 
common complications of wound dressings, rather 
than improving time to wound closure. One RCT, 
which did not meet inclusion criteria, found no 
difference in wound resolution for three different 
dressings, despite large cost disparities [43]. 
Ultimately, there is insufficient evidence to support 
which type of dressing best maintains a moist, 
occlusive wound healing environment. 
 
1.3.2 Topical Therapies 
 
Topical therapies include a range of therapeutic 
cutaneous applications aimed at improving wound 
healing by various mechanisms. 
An RCT failed to demonstrate a significant 
difference in overall healing and amputation rates 
after application of topical honey. However, honey 
therapy significantly increased healing rate 
compared with povidone iodine dressings (p\0.0001) 
[44]. A systematic review by Shaw et al. [45] 
evaluated topical phenytoin but only 2 of the 14 
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studies were specific for DFU, and only one of 
which demonstrated statistically significant 
reduction in wound size. A sponsored phase II RCT 
of NorLeu3-A, an angiotensin analog, showed 
promising results, with DFUs healing at a median of 
8.5 weeks compared with 22 weeks in placebo (p = 
0.04) [46]. Lastly, a meta-analysis of hyaluronic acid 
(HA) evaluated four DFU-specific studies [47]. Two 
RCTs analyzed HA scaffolding with keratinocytes 
versus standard of care in DFUs, with a primary 
outcome of complete healing at 12 weeks. Neither 
study demonstrated statistically significant 
improvement, though a trend towards healing was 
observed (RR 0.90; 95 % CI 0.76–1.04; p-value 
0.25). Two additional studies evaluated HA matrix 
alone versus standard of care in neuropathic ulcers. 
Meta-analysis of these studies found improved 
healing rates at 12 weeks post-treatment (RR 0.24; 
95 % CI 0.24–0.49; p-value \0.0001) with fewer 
non-healed ulcers in the HA group [47]. Systematic 
reviews looking at various methods of topical 
therapy were not able to find a comprehensive 
analysis comparing each method, nor were they able 
to determine one superior therapy [34, 35]. 
 
Summary: There is moderate-quality evidence to 
support the use of various topical therapies; 
however, the strength of recommendation is low 
given study limitations and lack of comparative 
efficacy trials. 
 
1.3.3 Electrophysical Therapy 
Electrophysical therapy is an umbrella term for 
various treatments delivered by transmittal of energy 
from electrical, ultrasound, light/laser, and 
electromagnetic sources. Electrical stimulation 
wound therapy (ESWT) produces shortpulse 
electrical stimuli intended to mimic the body’s 
natural electrical system and stimulate wound repair. 
Electrical stimulation may also improve perfusion, 
which can also contribute to improving healing. It 
may also stimulate the migration of various wound-
modifying cells including keratinocytes, fibroblasts, 
macrophages, and neutrophils via various signaling 
mechanisms [48]. Unfortunately, multiple different 
methods for electrical stimulation have been used 
clinically, with widely varying physiological 
rationales, making comparisons between studies 
difficult. 
Nevertheless, a single meta-analysis evaluated 
various electrophysical modalities, including ESWT, 
phototherapy, and ultrasound in treatment of DFUs 
and found statistically significant evidence to 
support their use (p = 0.002) [49]. Two additional 
systematic reviews evaluated electrical stimulation 
and shockwave therapy RCTs and determined the 
majority of the studies to be too methodologically 
weak or lacking in sample size to provide 
statistically significant results [34, 35]. Only one 
study was able to show an improved trend towards 
healing at 12 weeks with electrical stimulation [34]. 
Summary: These studies were conducted with 
moderate quality of evidence. Unfortunately, few 
conclusions could be drawn from these reports given 
the small sample size and poor methodological 
quality of the included studies. Kwan et al. [49] 
concluded that there was enough preliminary 
evidence to support larger randomized trials. 
 
1.3.4 Negative Pressure Wound Therapy 
Five systematic reviews compared NPWT with 
standard care or advanced moist wound therapy for 
DFUs and nonhealing post-amputation wounds in 
diabetic patients [34, 35, 50–52]. Game et al. [35] 
reported that two methodologically sound RCTs 
reported improved healing times and reduced risk of 
minor amputations with NPWT. An expert panel 
formulated recommendations based on the available 
literature and determined that NPWT should be 
considered in the following situations: (1) for post-
operative Texas grade 2 and 3 diabetic foot wounds 
without ischemia, (2) to prevent amputation or re-
amputation, and (3) to facilitate healing by 
secondary intention [52]. 
Many of the reviewed trials were of poor to 
moderate quality, and the systems and methods of 
applying therapies used were heterogeneous. None 
of the studies examined change in bacterial 
colonization of the wounds, participant quality of 
life, or cost effectiveness. 
 
Summary: Moderate-quality evidence suggests that 
NPWTs improve healing of DFUs and non-healing 
postamputation wounds compared with standard 
wound care. Many questions remain regarding ideal 
patient population and cost effectiveness. 
 
1.3.5 Platelet-Rich Plasma, Cultured 
Keratinocytes, Growth Factors, and 
Skin Substitutes 
Among other elements, wound healing requires a 
functional wound bed. Topical growth factors and 
BSS target the aberrant wound bed of a chronic 
ulcer to stimulate intrinsic epidermal and dermal 
elements necessary for healing of chronic wounds. 
 
1.3.5.1 Platelet-Rich Plasma  
A 2012 Cochrane review did not find statistically 
significant evidence to support the use of PRP in 
treating chronic wounds [53]. Two of the RCTs 
included in the Cochrane study were DFU specific 
and did not find a statistically significant difference 
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between PRP and control in DFU treatment (RR 
1.16; 95 % CI 0.57–2.35). Overall, the study was 
unable to establish evidence-based support of PRP 
by ulcer etiology or by the procedure used to obtain 
autologous PRP. 
A separate meta-analysis of five RCTs 
comparing DFUspecific healing found the use of 
PRP to be an effective adjunctive therapy in wound 
healing (95 % CI 2.94–20.31) only if used in 
combination with other therapies in a 
multidisciplinary approach [54]. Of note, the study 
was unable to establish a reference value for PRP 
concentration consistent with each study and was 
therefore unable to recommend a therapeutic dose 
for DFU treatment [54]. Lastly, two additional 
systematic reviews found six studies addressing the 
use of PRP in wounds but were unable to determine 
significant benefit given the limitations of the 
studies, which included sample size, poorly 
established endpoints, and elaborate exclusion 
criteria. One RCT did find improved healing at 12 
weeks (intervention 79 % vs. control 46 %; p\0.05); 
time to healing (intervention 7.0 ± standard 
deviation [SD] 1.9 vs. 9.2 ± 2.2 weeks; p < 0.05); 
and percent area reduction (intervention 96.3 ± 7.8 
vs. control 81.6 ± 19.7; p < 0.05). However, 
reviewers stated that thestudy’sinclusion and 
exclusion criteria were unclear and were surprised 
by healing rates given the high incidence of bone 
exposure in pre-treatment wounds [34, 35].  
 
1.3.5.2  Allogeneic Keratinocytes 
Living skin equivalents comprise live skin cells that 
release growth factors prompting new growth. In an 
RCT, allogeneic neonatal foreskin keratinocytes 
achieved complete wound closure in 100 % of DFUs 
versus 69 % of control patients (p\0.05) [55]. The 
experimental group also had shorter healing time (35 
days) than the control group (57 days). However, 
this study was single-blind, and the etiology of each 
ulcer was not sufficiently ruled out for possible 
neuro-ischemia. The authors acknowledged the 
necessity for larger studies and the need for DFU 
standard of care, including debridement and 
infection control, as essential to healing outcomes 
[55]. Two additional systematic reviews found two 
separate RCTs comparing allogenic keratinocytes; 
however, both lack of complete data set and poor 
methodology prevented further analysis [34, 35]. 
 
1.3.5.3 Growth Factors 
Three systematic reviews evaluated the use of 
growth factors for DFUs [34, 35, 56]. A systematic 
review of growth factors and BSS included nine 
RCTs of growth factors. Studied growth factors 
included becaplermin (n = 6), recombinant human 
epidermal growth factor (rhEGF, n = 2), and basic 
fibroblast growth factor (bFGF) (n = 1) [56]. All 
described studies had significant methodological 
limitations, including in some lack of blinding and 
failure to provide sample size calculations. 
Becaplermin, a recombinant platelet-derived growth 
factor, is the only US FDA-approved drug for 
treatment of DFUs and has been shown to 
significantly increase the proportion of healed ulcers 
and decrease healing time when used as adjuvant 
therapy with standard wound care (p\0.05 in three 
RCTs and two meta-analyses). In a non-inferiority 
study, no statistically significant difference in 
effectiveness was seen between becaplermin and 
porcine small intestine submucosa, an advanced 
wound matrix implant (p = 0.245). Therapy with 
rhEGF (0.04 and 0.015 %) was significantly superior 
to standard wound care plus placebo in two trials. 
One study that compared bFGF with standard 
wound care failed to find a benefit of bFGF. 
 
 
1.3.5.4    Bioengineered Skin Substitutes and Skin 
Grafting 
Six reviews evaluated BSS for the treatment of 
DFUs [34, 35, 56–59]. All found BSS superior to 
standard wound care; however, these conclusions 
were based on studies of limited quality. Two 
cellular constructs are commercially available in the 
USA: a dermal equivalent (Dermagraft
TM
, Shire, La 
Jolla, CA, USA) and a bilayered construct 
(Apligraf
TM
, Organogenesis, Canton, MA, USA) and 
were found superior to standard wound care. Two 
reviews reported processed cadaveric acellullar 
dermis (GraftJacket
TM
, KCI, San Antonio, TX, 
USA) superior to standard wound care [56, 57]. 
Promogran
TM
, a composite of collagen and oxidized 
regenerated cellulose (Systagenix, Gatwick, West 
Sussex, UK), (n = 1) and Hyalograft
TM
, cultured 
autologous fibroblasts seeded onto an HA-derived 
scaffold (Anika Therapeutics, Bedford, MA, USA), 
(n = 1) were not significantly superior to standard 
therapy [58]. However, Teng et al. [57] suggest that 
the lack of significant effect in the study of 
Hyalograft
TM
 may be due to an inadequate number 
of applications. In this study, Hyalograft
TM
 was 
applied only one to two times, significantly 
fewerthanin all other studies. No evidence of 
increased adverse events was reported in the 
reviewed studies. 
 
Summary: Only limited conclusions can be drawn 
from these studies given that reviewed studies had 
multiple methodological limitations. Available data 
suggest that the addition of growth factors and 
metabolically active BSS Dermagraft
@
, Apligraf
@
, 
and GraftJacket
@
 increases the likelihood of 
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complete ulcer healing. This effect may be dose 
dependent. 
 
1.3.6 Hyperbaric Oxygen Therapy 
Adjunctive treatment with systemic HBOT is 
thought to accelerate wound healing by reducing 
tissue hypoxia [60]. Patients are placed in a 
compression chamber of 100 % oxygen at a pressure 
of at least 1.4 ATM. The oxygen dose and number 
of sessions are not standardized and vary between 
studies. Kranke et al. [61], for example, evaluated 
eight trials: seven used chamber pressures ranging 
from 2.2 to 3.0 ATA and sessions lasted between 
45–120 min. Most trials included between 20 and 40 
sessions, while one trial used only four sessions over 
2 weeks. 
Two recent systematic reviews [62, 63] that 
included both prospective and retrospective studies 
concluded that adjunctive therapy with HBOT 
significantly increased the likelihood of ulcer 
healing (RR 2.33, 95 % CI 1.51–3.60) [63] and 
significantly reduced the risk of major amputation 
(RR 0.29 95 % CI 0.19–0.44), with benefits 
persisting at the 1- to 3-year follow-up (RR of 
healing 2.97, p<0.01.) Game et al. [35] note that 
high-quality evidence is limited, but a 
methodologically sound study found that subjects 
receiving HBOT were significantly more likely to 
heal within 12 months (p = 0.03). However, a 2012 
Cochrane review limited to RCTs found that while 
HBOT increased healing of DFUs evaluated at 6 
weeks (RR 5.20, 95 % CI 1.25–21.66; p = 0.02,), 
this benefit was no longer evident at 1-year follow-
up [61]. Furthermore, the Cochrane review did not 
find that HBOT decreased the risk of major 
amputations (RR 0.36, 95 % CI 0.11–1.18; p = 
0.08). 
Differences in data analysis and study selection 
among reviews likely explain these discrepancies. 
The Cochrane review was limited to RCTs, while 
the other two reviews also included non-randomized 
and retrospective studies, which increased the 
study’s power at the expense of introducing bias into 
the analyses. Also, because individual trials were 
heterogeneous in patient populations, outcomes 
measures, and ulcer characteristics, the reviewers 
selectively chose to exclude some trials from their 
analysis. Liu et al. [35] excluded one RCT from 
their analysis because it reported healing outcomes 
only with conservative measures, excluding those 
requiring surgery. This increases the likelihood of 
detecting a protective effect of HBOT on risk of 
amputation. Also, when Kranke et al. [35] repeated 
their analysis without one trial of patients at high 
risk for amputation, their analysis did reveal a 
significant reduction of major amputation risk with 
HBOT therapy (p = 0.0009.) Due to the limited 
number of available studies, these small differences 
in analyses can significantly affect the results. 
These discrepancies highlight the need for future, 
methodologically rigorous, appropriately powered, 
and methodologically standardized studies. 
 
Summary: HBOT is frequently used, but because 
of a lack of a definitive efficacy study or well done 
effectiveness studies, this treatment remains, as 
Margolis and colleagues have pointed out in their 
recent analysis, controversial [66, 67]. More 
research is necessary to define the patient population 
that would most benefit from this therapy. The 
finding that the benefits of HBOT may be limited to 
shortterm follow-up should be further explored, as 
this may have significant implications regarding the 
cost effectiveness of this intervention. 
 
1.3.7 Alternative Therapy 
Only two systematic reviews were found that 
evaluated evidence for adjunctive oral Chinese 
herbal therapies [35, 68]. Meta-analysis of six 
studies studying different oral herbal preparations 
suggests that adding Chinese herbal medications to 
standard therapy improvesthe like lihood of 
complete ulcer healing (RR 0.62, 95 % CI 0.39–
0.97) [68]. Side effects of therapy were mild, and 
adverse events were not significantly different 
between groups. Topical herbal preparations were 
not included in this analysis. Five of the six 
individual trials were judged to be of low quality, 
and only one was a randomized, double-blinded 
trial. Also, the herbal remedies were different across 
studies, making comparison and clinical 
recommendations difficult. The authors note that the 
most frequently used herbs were Radix Angelicae 
sinensis, Flos Carthami Tinctorii, Semen Persicae, 
and Radix astragal. 
Another review noted that an oral Chinese herbal 
formulation did not improve healing of 
necrotic/gangrenous ulcers compared with placebo. 
The same review noted that ANGIPARS
TM
 herbal 
preparation (administered orally, topically, or 
intravenously) improved healing of DFUs, but 
supporting studies were methodologically flawed 
[35]. 
 
Summary: Evidence is insufficient to make clinical 
recommendations regarding the safety or efficacy of 
oral Chinese oral supplements when used 
adjunctively with standard wound therapy. 
 
1.4 Limitations 
 
Comparison of different treatment modalities is 
difficult since existing studies are not standardized. 
Notably, this review focuses exclusively on 
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evidence supporting treatment and excludes other 
data that may be critical to clinical decision making, 
such as side effects, cost, and applicability to 
practice setting. We also acknowledge the limitation 
that only including English-language papers 
introduces bias to our results. 
 
 
4 CONCLUSIONS 
Good-quality evidence is lacking for many of the 
described treatment modalities, and future studies 
are critical to better define the indications, 
therapeutic benefits, and adverse effects of each 
intervention. Given the diversity of therapies, future 
studies must define the populations that most benefit 
from each therapy by utilizing clear and strict 
inclusion and exclusion criteria. Also, baseline 
subject and ulcer characteristics should be described 
to allow comparison among trials and to define the 
indications of each modality. This is especially 
relevant to justify the use of new and expensive 
therapies that may be appropriate only for specific 
subsets of patients. Future study protocols should 
also incorporate a comprehensive set of outcome 
measures, including complete wound healing, 
wound healing rate, ulcer recurrence, pain, cost 
effectiveness, and quality of life. Most studies 
described in this review only evaluate healing rate or 
complete healing and disregard impact on quality of 
life and cost effectiveness. Given that compliance 
has been shown to be a critical factor in treatment 
success, parameters such as pain and quality of life 
should be evaluated. Of note, future studies should 
include subgroup analysis to evaluate treatment 
efficacy stratified by subject characteristics, 
including subject age, sex, smoking history, body 
mass index, and diabetes control. A recently 
published study protocol meets each of these criteria 
[69]. 
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